182 related articles for article (PubMed ID: 1653394)
1. Inhibition of DNA synthesis in varicella-zoster virus-infected cells by BV-araU.
Machida H; Watanabe Y
Microbiol Immunol; 1991; 35(2):139-45. PubMed ID: 1653394
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the selectivity of anti-varicella-zoster virus nucleoside analogues.
Machida H; Nishitani M; Watanabe Y; Yoshimura Y; Kano F; Sakata S
Microbiol Immunol; 1995; 39(3):201-6. PubMed ID: 7603364
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Yokota T; Konno K; Mori S; Shigeta S; Kumagai M; Watanabe Y; Machida H
Mol Pharmacol; 1989 Aug; 36(2):312-6. PubMed ID: 2549386
[TBL] [Abstract][Full Text] [Related]
4. Effect of BV-araU and acyclovir on varicella-zoster virus replication with various length and timing of drug exposure.
Machida H; Nishitani M; Ashida N
Microbiol Immunol; 1994; 38(2):109-15. PubMed ID: 8041297
[TBL] [Abstract][Full Text] [Related]
5. Metabolic fate of [3H]1-beta-D-arabinofuranosyl-5-[(E)-2-bromovinyl]uracil in herpes simplex virus type 1-infected cells.
Ashida N; Sakata S; Machida H
Microbiol Immunol; 1997; 41(12):957-64. PubMed ID: 9492181
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against thymidine kinase negative strains of varicella-zoster virus.
Kawai H; Yoshida I; Suzutani T
Microbiol Immunol; 1993; 37(11):877-82. PubMed ID: 8295566
[TBL] [Abstract][Full Text] [Related]
7. Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Sakuma T
Antimicrob Agents Chemother; 1984 Jun; 25(6):742-6. PubMed ID: 6331298
[TBL] [Abstract][Full Text] [Related]
8. Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines.
Machida H; Ijichi K; Ohta A; Honda M; Niimura M
Microbiol Immunol; 1990; 34(11):959-65. PubMed ID: 1965323
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of varicella-zoster virus to thymidine analogues.
Machida H
Biken J; 1986 Mar; 29(1):1-6. PubMed ID: 3022708
[TBL] [Abstract][Full Text] [Related]
10. Effects of various nucleosides on antiviral activity and metabolism of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus types 1 and 2.
Suzutani T; Machida H; Sakuma T; Azuma M
Antimicrob Agents Chemother; 1988 Oct; 32(10):1547-51. PubMed ID: 2847634
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of plaque formation of herpes simplex virus (HSV) and varicella-zoster virus (VZV) by subinhibitory dose of acyclovir (ACV).
Shiraki K; Miyaki C; Namazue J; Yamanishi K; Takahashi M
Acta Virol; 1989 Dec; 33(6):565-8. PubMed ID: 2576598
[TBL] [Abstract][Full Text] [Related]
12. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.
Earnshaw DL; Bacon TH; Darlison SJ; Edmonds K; Perkins RM; Vere Hodge RA
Antimicrob Agents Chemother; 1992 Dec; 36(12):2747-57. PubMed ID: 1336346
[TBL] [Abstract][Full Text] [Related]
13. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes.
Koyano S; Suzutani T; Yoshida I; Azuma M
Antimicrob Agents Chemother; 1996 Apr; 40(4):920-3. PubMed ID: 8849252
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds.
Machida H; Sakata S
Antiviral Res; 1984 Jun; 4(3):135-41. PubMed ID: 6089657
[TBL] [Abstract][Full Text] [Related]
15. Different antiviral potencies of BV-araU and related nucleoside analogues against herpes simplex virus type 1 in human cell lines and Vero cells.
Machida H; Nishitani M; Suzutani T; Hayashi K
Microbiol Immunol; 1991; 35(11):963-73. PubMed ID: 1663576
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship between (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BV-araU, V-araU) in inhibition of Epstein-Barr virus replication.
Lin JC; Reefschläger J; Herrmann G; Pagano JS
Antiviral Res; 1992 Jan; 17(1):43-52. PubMed ID: 1310582
[TBL] [Abstract][Full Text] [Related]
17. Topical treatment with BV-araU of immunosuppressed and immunocompetent shaved mice cutaneously infected with herpes simplex virus type 1.
Ijichi K; Ashida N; Varia S; Machida H
Antiviral Res; 1993 May; 21(1):47-57. PubMed ID: 8391248
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of the affinity of 5-substituted uracil nucleoside analogues for varicella-zoster virus thymidine kinase and their activity against varicella-zoster virus.
Ashida N; Watanabe Y; Miura S; Kano F; Sakata S; Yamaguchi T; Suzutani T; Machida H
Antiviral Res; 1997 Aug; 35(3):167-75. PubMed ID: 9298756
[TBL] [Abstract][Full Text] [Related]
19. Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
Shiraki K; Tan L; Daikoku T; Takemoto M; Sato N; Yoshida Y
Antiviral Res; 2020 Aug; 180():104829. PubMed ID: 32569704
[TBL] [Abstract][Full Text] [Related]
20. Antiviral activity of the 3'-amino derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
De Clercq E; Descamps J; Balzarini J; Fukui T; Allaudeen HS
Biochem J; 1983 May; 211(2):439-45. PubMed ID: 6307280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
